Marinus Moerland

Dr. Marinus Moerland


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MMMarinus Moerland
Marinus Moerland
MDMarijke J.H. van Deursen
Marijke J.H. van Deursen
SESjoerd G. Elias
Sjoerd G. Elias
MVMarco van Vulpen
Marco van Vulpen
IJIna M. Jürgenliemk-Schulz
Ina M. Jürgenliemk-Schulz
JBJan J. Battermann
Jan J. Battermann

3 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MRMarnix JA Rasing
Marnix JA Rasing
MSMarieke van Son
Marieke van Son
MMMarinus Moerland
Marinus Moerland
BKBart De Keizer
Bart De Keizer
FWFrank Wessels
Frank Wessels
MPMax Peters
Max Peters
Radiorecurrent prostate cancer is conventionally confirmed using systematic and/or targeted biopsies. The availability of multiparametric (mp) MRI and prostate specific membrane antigen (PSMA) PET/CT has increased diagnostic accuracy. The objective was to determine the positive predictive value (PPV) of combined mp-MRI and PSMA PET/CT and whether pathology verification with MR-targeted biopsies remains necessary for patients with radiorecurrent prostate cancer. Patients with locally recurrent prostate cancer who were referred for 19 Gy single-dose MRI-guided focal salvage high dose rate (HDR) brachytherapy between 2015 and 2018 were included in the current analysis. Patients were selected if they underwent pre-biopsy mp-MRI and PSMA PET/CT. Based on these images, lesions suspect for isolated tumor recurrence were transperineally biopsied using transrectal ultrasound fused with MRI. A total of 41 patients were identified from the database who underwent cognitive targeted (n = 7) or MRI/PSMA-transrectal ultrasound (TRUS) fused targeted (n = 34) biopsies. A total of 40 (97.6%) patients had positive biopsies for recurrent cancer. Five patients initially had negative biopsies (all MRI/PSMA-TRUS fusion targeted), four of whom recurrence was confirmed after a re-biopsy. One (2.4%) patient refused re-biopsy, leading to a positive predictive value (PPV) for combined imaging of 97.6%. Biopsies can therefore safely be withheld when the results of the combined mp-MRI and PSMA PET/CT are conclusive, avoiding an unnecessary invasive and burdensome procedure.

3 December 2018 in Cancers
Verified
Journal Article
Open access
PDF file
MSMarieke Van Son
Marieke Van Son
MPMax Peters
Max Peters
MMMarinus Moerland
Marinus Moerland
LKLinda Kerkmeijer
Linda Kerkmeijer
JLJan Lagendijk
Jan Lagendijk
JZJochem Van der Voort van Zyp
Jochem Van der Voort van Zyp
Over the last decades, primary prostate cancer radiotherapy saw improving developments, such as more conformal dose administration and hypofractionated treatment regimens. Still, prostate cancer recurrences after whole-gland radiotherapy remain common, especially in patients with intermediate- to high-risk disease. The vast majority of these patients are treated palliatively with androgen deprivation therapy (ADT), which exposes them to harmful side-effects and is only effective for a limited amount of time. For patients with a localized recurrent tumor and no signs of metastatic disease, local treatment with curative intent seems more rational. However, whole-gland salvage treatments such as salvage radiotherapy or salvage prostatectomy are associated with significant toxicity and are, therefore, uncommonly performed. Treatments that are solely aimed at the recurrent tumor itself, thereby better sparing the surrounding organs at risk, potentially provide a safer salvage treatment option in terms of toxicity. To achieve such tumor-targeted treatment, imaging developments have made it possible to better exclude metastatic disease and accurately discriminate the tumor. Currently, focal salvage treatment is being performed with different modalities, including brachytherapy, cryotherapy, high-intensity focused ultrasound (HIFU), and stereotactic body radiation therapy (SBRT). Oncologic outcomes seem comparable to whole-gland salvage series, but with much lower toxicity rates. In terms of oncologic control, these results will improve further with better understanding of patient selection. Other developments, such as high-field diagnostic MRI and live adaptive MRI-guided radiotherapy, will further improve precision of the treatment.

1 January 2018 in Brachytherapy
Verified
Journal Article
Closed access
MMMetha Maenhout
Metha Maenhout
JZJochem R.N. van der Voort van Zyp
Jochem R.N. van der Voort van Zyp
MBMaxence Borot de Battisti
Maxence Borot de Battisti
MPMax Peters
Max Peters
MVMarco van Vulpen
Marco van Vulpen
MMMarinus Moerland
Marinus Moerland

5 April 2018 in Cureus
Verified
Journal Article
Open access
PDF file
MSMarieke Van Son
Marieke Van Son
MPMax Peters
Max Peters
MMMarinus Moerland
Marinus Moerland
JNJuus L. Noteboom
Juus L. Noteboom
WEWietse S. Eppinga
Wietse S. Eppinga
JZJochem R. Van der Voort van Zyp
Jochem R. Van der Voort van Zyp
Prostate cancer recurrences are common, even with twenty-first-century primary prostate cancer treatment modalities. The most common salvage treatment is (delayed) hormonal therapy, which is often associated with serious side-effects. Due to the risk of significant toxicity, whole-gland targeted salvage treatments remain unpopular. Consequently, developments in focal therapies have arisen. Magnetic resonance imaging (MRI)-guided focal salvage high-dose-rate brachytherapy (HDR-BT) is a novel treatment aiming for minimal toxicity in recurrent prostate cancer patients. Repeating focal treatment could, therefore, be possible in case of post-salvage recurrence. We report the case of a 77-year-old man who underwent repeat focal HDR-BT.

30 April 2013
Verified
Book Chapter
Closed access
PDF file
MMMarinus Moerland
Marinus Moerland